Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin

Jeffrey Freeman

Article Type

Case Report

Published

In this article the author discusses the implications for clinical practice of the results of a recent Phase III trial. He concludes that initial combination of linagliptin plus metformin which was found to be weight neutral, well tolerated and associated with a low frequency of hypoglycaemia, may have advantages for a large proportion of patients with type 2 diabetes, particularly those with a relatively high HbA1c at diagnosis.

Read more

Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes

Stanley S Schwartz

Article Type

Case Report

Published

In this article the author argues that in type 2 diabetes, an approach that emphasizes diet and exercise and features a treatment regimen tailored to the needs of the individual to reach glycemic targets is warranted in most patients and provides microvascular and cardiovascular benefit, provided that hypoglycemia is avoided.

Read more

Cardiovascular consequences of obesity: how will the UK cope?

Henry Purcell

Article Type

Case Report

Published

It is estimated that by 2050, the majority of Britain’s population will be obese. In this article, Dr Henry Purcell discusses the cardiovascular consequences of obesity and what needs to be done to equip healthcare professionals with the tools and training to help prevent and treat weight-related diseases.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.